Comparison of whole exome sequencing and FoundationOne Heme
sequencing panel as tools for precision oncology in paediatric
patients with difficult-to-treat solid tumours

a 2019

Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours

NOSKOVA, H., Soňa ADAMCOVÁ, Dana KNOFLÍČKOVÁ, Karol PÁL, Andrea GRIONI et. al.

Basic information

Original name

Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours

Authors

NOSKOVA, H., Soňa ADAMCOVÁ (703 Slovakia, belonging to the institution), Dana KNOFLÍČKOVÁ (203 Czech Republic, belonging to the institution), Karol PÁL (703 Slovakia, belonging to the institution), Andrea GRIONI (380 Italy, belonging to the institution), T. HORNAKOVA, T. MERTA, P. MUDRY, Z. PAVELKA, K. VEJMELKOVA, J. STERBA and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Conference on Molecular Analysis for Personalised Therapy (MAP), 2019

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 18.274

RIV identification code

RIV/00216224:14740/19:00108620

Organization unit

Central European Institute of Technology

ISSN

DOI

http://dx.doi.org/10.1093/annonc/mdz413.102

UT WoS

000496763900096

Keywords in English

exome sequencing

Abstract

V originále

The necessary condition for the application of precision oncology approach into the routine is a detailed molecular characterization of the tumour. In our study, we explored clinical applicability of both whole exome sequencing (WES) and FoundationOne Heme (F1Heme) panel (Foundation Medicine, Inc., MA, USA) as comprehensive genomic profiling tools in a cohort of 35 children with difficult-to-treat solid tumours.

Links

NV16-33209A, research and development project

Name: Sekvenování nové generace a expresní profilování jako diagnostický podklad pro návrhy individualizovaných léčebných plánů pro děti se solidními nádory

Citovat

NOSKOVA, H., Soňa ADAMCOVÁ, Dana KNOFLÍČKOVÁ, Karol PÁL, Andrea GRIONI, T. HORNAKOVA, T. MERTA, P. MUDRY, Z. PAVELKA, K. VEJMELKOVA, J. STERBA and Ondřej SLABÝ. Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours. In Conference on Molecular Analysis for Personalised Therapy (MAP). 2019. ISSN 0923-7534. Available from: https://dx.doi.org/10.1093/annonc/mdz413.102.

@proceedings{1642620,
   author = {Noskova, H. and Adamcová, Soňa and Knoflíčková, Dana and Pál, Karol and Grioni, Andrea and Hornakova, T. and Merta, T. and Mudry, P. and Pavelka, Z. and Vejmelkova, K. and Sterba, J. and Slabý, Ondřej},
   booktitle = {Conference on Molecular Analysis for Personalised Therapy (MAP)},
   doi = {http://dx.doi.org/10.1093/annonc/mdz413.102},
   keywords = {exome sequencing},
   language = {eng},
   title = {Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours},
   year = {2019}
}

TY  - CONF
ID  - 1642620
AU  - Noskova, H. - Adamcová, Soňa - Knoflíčková, Dana - Pál, Karol - Grioni, Andrea - Hornakova, T. - Merta, T. - Mudry, P. - Pavelka, Z. - Vejmelkova, K. - Sterba, J. - Slabý, Ondřej
PY  - 2019
TI  - Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours
KW  - exome sequencing
N2  - The necessary condition for the application of precision oncology approach into the routine is a detailed molecular characterization of the tumour. In our study, we explored clinical applicability of both whole exome sequencing (WES) and FoundationOne Heme (F1Heme) panel (Foundation Medicine, Inc., MA, USA) as comprehensive genomic profiling tools in a cohort of 35 children with difficult-to-treat solid tumours.
ER  -

NOSKOVA, H., Soňa ADAMCOVÁ, Dana KNOFLÍČKOVÁ, Karol PÁL, Andrea GRIONI, T. HORNAKOVA, T. MERTA, P. MUDRY, Z. PAVELKA, K. VEJMELKOVA, J. STERBA and Ondřej SLABÝ. Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours. In \textit{Conference on Molecular Analysis for Personalised Therapy (MAP)}. 2019. ISSN~0923-7534. Available from: https://dx.doi.org/10.1093/annonc/mdz413.102.

Detailed Information on Publication Record